Preliminary unaudited Q4 and Full Year 2025 net Attruby®product revenue of $146.0 million and $362.4 million, respectively ...

The roof is one of the most expensive components of a commercial or industrial property. It protects everything inside yet, ...

Group calls for review of retailer’s partnership with Flock Safety, whose data has been used in ​immigration enforcement ...

This publication has not been sponsored or paid for by any external entities. The insights and perspectives shared are organic, reflecting the author's genuine viewpoints and professional expertise ...

The European Commission has approved BridgeBio's acoramidis for life-threatening heart disorder transthyretin amyloidosis cardiomyopathy (ATTR-CM), setting up a market clash with Pfizer. The oral drug ...

ARKF offers thematic returns through growth stock exposure, benefiting from pro-risk environments and tech rallies. See why ...

If you’ve been watching your analytics lately, you might have noticed a confusing trend: organic search numbers are dipping, ...

The successful commercialization of Attruby could establish BridgeBio as a key player in the ATTR-CM market, significantly improving its path to profitability.